查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1565035

醣體學/糖生物學的全球市場

Glycomics / Glycobiology
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 249 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球醣體學/糖生物學市場將達到 64 億美元

全球醣體學/糖生物學市場預計 2023 年為 21 億美元，預計到 2030 年將達到 64 億美元，2023-2030 年分析期間複合年成長率為 16.9%。酵素是本報告分析的細分市場之一，複合年成長率將達到 17.8%，預計到分析期結束時將達到 29 億美元。分析期間，套件和試劑細分市場的複合年成長率預計為 16.8%。

美國市場預估價值5.929億美元，中國預期複合年成長率16.0%

預計 2023 年美國醣體學/糖生物學市場規模將達 5.929 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達到9.664億美元，2023-2030年分析期間複合年成長率為16.0%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 14.9% 和 14.3%。在歐洲，德國的複合年成長率預計約為 12.2%。

全球醣體學/糖生物學市場 - 主要趨勢和促進因素總結

為什麼醣體學/糖生物學成為生物技術和醫學的一個主要領域？

醣體學，也稱為糖生物學，正在成為生物技術和醫學的一個重要領域，因為它在理解複雜的生物過程和推進治療方法發揮關鍵作用。但為什麼醣體學在今天如此重要呢？糖生物學是一個全面研究糖鏈的研究領域，糖鏈是與蛋白質和脂質結合的複雜碳水化合物，參與細胞訊號傳導、免疫反應和疾病進展等多種生物功能。糖生物學專注於這些糖分子如何影響細胞通訊、疾病機制以及新診斷和治療方法的開發。

糖生物學的研究對人類健康有廣泛的影響，因為聚醣在癌症、自體免疫疾病和感染疾病等疾病的進展中發揮著重要作用。透過破解聚醣的結構和功能，研究人員正在發現早期診斷疾病、開發更有針對性的治療方法以及開發更有效的疫苗的新方法。此外，醣質學對於理解藥物交互作用和設計生技藥品至關重要，而生物製劑正成為精準醫學的重要工具。隨著個人化醫療保健變得越來越重要，醣質學正在幫助揭示身體在分子層面上如何運作的新見解，推動診斷、治療和疫苗開發的創新。

科技進步如何加速醣質學的研究與應用？

技術進步在推進醣質學研究方面發揮著至關重要的作用，使破解聚醣的複雜性並揭示其在生物系統中的多樣化功能成為可能。一項重要的進展是高通量聚醣分析技術的發展，例如層析法(LC)，這使得聚醣結構的快速識別和表徵成為可能。這些工具使研究人員能夠比以往更快、更精確地繪製生物體或組織中的聚醣或醣組圖。這種能力對於理解聚醣在組織、個體和疾病狀態之間的差異至關重要，為更個人化的治療鋪平了道路。

另一項重要的技術進步是將生物資訊工具應用於醣質學研究。聚醣結構複雜，具有眾多的分支和多樣化的組成，需要複雜的計算方法來分析和解釋。機器學習和人工智慧 (AI) 的進步使得開發能夠預測聚醣結構與蛋白質和脂質之間相互作用的演算法成為可能。這些生物資訊工具將幫助研究人員識別疾病的聚醣生物標記物，開發基於聚醣的療法，並揭示聚醣變化如何參與疾病進展。人工智慧主導的分析使科學家能夠篩選大量的聚醣資料，以更有效地識別模式和潛在的治療標靶。

合成糖生物學的進步也透過實現合成聚醣的設計和生產而改變了這個領域。這些合成聚醣模仿天然存在的分子，用於疫苗開發、藥物發現和治療研究。例如，研究人員可以創建特定的聚醣結構來研究病原體如何與人類細胞相互作用或開發引發強烈免疫反應的疫苗。這種能力對於開發針對流感和冠狀病毒等複雜病毒的疫苗尤其重要，其中聚醣在免疫逃脫中發揮關鍵作用。此外，合成聚醣可用於開發針對癌細胞上特定受體或調節免疫反應的基於聚醣的藥物，為精準醫學開闢新途徑。

另一個進展領域是使用先進的成像技術，例如冷凍電子顯微鏡（cryo-EM）和聚醣陣列技術。這些工具使我們能夠在分子層面上可視化聚醣如何與其他生物分子相互作用。這對於理解聚醣在細胞訊號傳導、病原體識別和免疫系統功能等過程中的作用至關重要。例如，聚醣陣列能夠高通量篩檢碳水化合物與蛋白質的相互作用，從而揭示癌症和神經退化性疾病等疾病的潛在藥物標靶和生物標記。這些影像和篩檢技術可以更深入地了解聚醣在健康和疾病中的動態作用。

為什麼醣質學對於闡明疾病機制、開發診斷方法和推進治療方法至關重要？

由於聚醣在控制生物過程和疾病進展中發揮重要作用，因此醣質學對於了解疾病機制、開發診斷方法和推進治療方法至關重要。聚醣幾乎參與細胞功能的各個方面，從蛋白質折疊和穩定性到免疫系統活化和細胞間通訊。聚醣結構的變化通常與疾病狀態有關，這使得醣體學成為在分子層面上識別生物標記和了解疾病機制的寶貴工具。

醣質學對醫學最重要的貢獻之一是能夠發現用於早期檢測疾病的生物標記。糖基化（糖鏈附著在蛋白質和脂質上的過程）的變化經常在癌症、糖尿病和感染疾病等疾病中觀察到。例如，異常的聚醣模式是癌細胞的標誌，可以促進腫瘤生長、轉移和免疫逃脫。透過識別這些改變的聚醣特徵，研究人員可以開發出更靈敏、更特異性的診斷測試。基於聚醣的生物標記有可能徹底改變早期疾病檢測，使臨床醫生能夠識別癌症、肝病和神經退化性疾病等具有高治療潛力的疾病，從而實現早期診斷。

在治療方面，醣體學正在幫助開發更有針對性和更有效的治療方法。聚醣結構可以作為藥物的靶點，特別是在涉及異常糖基化的疾病中。例如，某些類型的癌症在其表面蛋白上表現出特異性的聚醣模式，而醣質學研究已經開發出特異性針對這些異常聚醣的治療方法。這些針對聚醣的治療提供了一種更精確的治療方法，專注於患病細胞，同時最大限度地減少對健康組織的損害。醣組學也有助於設計基於聚醣的疫苗，增強對病原體和癌細胞的免疫識別。聚醣在免疫系統識別外敵方面發揮重要作用，含有合成聚醣的疫苗可以引發更強、更特異性的免疫反應。

糖工程對於生技藥品的開發也至關重要，生物製劑是一類不斷成長的治療方法，包括單株抗體、基因療法和基於細胞的療法。許多生技藥品（例如治療性抗體）的穩定性、有效性和安全性都依賴糖基化。了解和控制藥物製造過程中的糖基化模式對於確保生技藥品正確發揮作用並對患者安全至關重要。 Glycomics 提供了在生產過程中監測和最佳化糖基化所需的工具，幫助製藥公司開發更有效且一致的生物製藥。

除了治療和診斷藥物之外，糖組學在個人化醫療的進步中也發揮著至關重要的作用。由於遺傳和環境因素的不同，聚醣模式可能有所不同，因此了解這些變化可以幫助開發針對患者獨特的聚醣譜的個人化治療。這對於癌症尤其重要，因為腫瘤通常表現出特異性的聚醣模式，並且可以針對個人化治療進行針對性治療。隨著醣體學領域的不斷發展，它將在塑造精準醫學的未來方面發揮越來越重要的作用，從而實現根據個別患者的分子特徵客製化更有效的治療方法。

推動醣質學/糖生物學市場成長的因素有哪些？

醣體學/糖生物學市場的快速成長是由幾個關鍵因素推動的，包括個人化醫療需求的不斷成長、藥物開發的進步、複雜疾病盛行率的增加以及聚醣分析的技術創新等因素。首先，個人化醫療的推廣是醣質學市場的促進因素。隨著醫療保健從一刀切的方法轉向更個人化的治療，醣體學提供了工具來識別可用於個人化治療的獨特聚醣譜。這在腫瘤學中尤其重要，因為癌細胞經常表現出特異性的聚醣改變，並且可以針對這些變化進行更有效的治療。用於早期疾病檢測和個人化治療策略的聚醣生物標記的可用性正在增加研究和臨床環境中對醣體學技術的需求。

其次，藥物開發的進步，特別是生技藥品和單株抗體領域的進步，正在促進醣體學市場的成長。許多生物製藥的活性、穩定性和安全性都依賴糖基化，在藥物製造過程中控制這些糖基化結構對於創造有效的治療方法至關重要。製藥公司正在增加對醣質學工具和技術的投資，以最佳化生物製藥的糖基化，並確保這些治療符合最高的功效和安全標準。這種對藥物開發精度的需求正在推動醣質學在製藥業的應用。

第三，癌症、自體免疫疾病和神經退化性疾病等複雜疾病的日益普及正在推動對先進診斷和治療解決方案的需求。醣體學具有獨特的優勢，可以深入了解付加的變化如何參與疾病進展，從而滿足這一需求。例如，基於聚醣的生物標記正在開發用於癌症的早期檢測，並且正在研究針對聚醣的治療方法作為自體免疫疾病和感染疾病的新治療方法。隨著這些疾病的全球負擔持續增加，對基於醣體學的解決方案的需求預計將顯著成長。

聚醣分析的技術創新也支持醣體學市場的擴張。質譜、聚醣陣列和生物資訊學工具的進步使研究人員能夠更快、更準確、更高解析度地分析聚醣。這些技術使科學家能夠更輕鬆地繪製糖組圖、識別疾病特異性聚醣變化以及開發新的基於聚醣的治療方法。高通量聚醣分析工具的日益普及正在加速研究並擴大醣體學在診斷、治療和疫苗開發等領域的商業性潛力。

此外，增加醣體學研究資金和建立專門的醣體學研究中心也有助於市場成長。政府、學術機構和私人公司正在大力投資醣質學學研究，因為它具有改變醫療保健的潛力。學術界、工業界和醫療保健提供者之間的合作正在推動醣質學在臨床中的應用，進一步推動對醣質學工具和技術的需求。

總之，醣體學/糖生物學市場的成長是由個人化醫療需求的增加、藥物開發的進步、複雜疾病盛行率的增加以及聚醣分析的技術創新所推動的。隨著醣體學繼續深入了解聚醣在健康和疾病中的作用，它將在塑造廣泛的醫療和工業應用中的診斷、治療和精準醫學的未來方面發揮重要作用。

受訪企業範例（共152家）

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他領域

第4章 比賽

簡介目錄
Product Code: MCP12203

Global Glycomics / Glycobiology Market to Reach US$6.4 Billion by 2030

The global market for Glycomics / Glycobiology estimated at US$2.1 Billion in the year 2023, is expected to reach US$6.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2023-2030. Enzymes, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Kits & Reagents segment is estimated at 16.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$592.9 Million While China is Forecast to Grow at 16.0% CAGR

The Glycomics / Glycobiology market in the U.S. is estimated at US$592.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$966.4 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.

Global Glycomics / Glycobiology Market - Key Trends and Drivers Summarized

Why Is Glycomics/Glycobiology Emerging as a Key Field in Biotechnology and Medicine?

Glycomics, also referred to as glycobiology, is becoming an essential field in biotechnology and medicine due to its critical role in understanding complex biological processes and advancing therapeutic solutions. But why is glycomics so vital today? Glycomics is the comprehensive study of glycans—complex carbohydrates that attach to proteins and lipids and are involved in a wide variety of biological functions, including cell signaling, immune response, and disease progression. Glycobiology focuses on how these sugar molecules influence cellular communication, disease mechanisms, and the development of new diagnostics and treatments.

The study of glycomics has far-reaching implications for human health, as glycans play a crucial role in the progression of diseases such as cancer, autoimmune disorders, and infections. By decoding the structure and function of glycans, researchers are uncovering new ways to diagnose diseases earlier, develop more targeted therapies, and create more effective vaccines. Moreover, glycomics is critical for understanding drug interactions and designing biologics, which are rapidly becoming essential tools in precision medicine. As the importance of personalized healthcare grows, glycomics is helping to unlock new insights into how the body functions at a molecular level, driving innovation in diagnostics, therapeutics, and vaccine development.

How Are Technological Advancements Accelerating Research and Applications in Glycomics?

Technological advancements are playing a pivotal role in advancing glycomics research, making it possible to decode the complexities of glycans and uncover their diverse functions in biological systems. One significant advancement is the development of high-throughput glycan analysis techniques, such as mass spectrometry (MS) and liquid chromatography (LC), which allow for the rapid identification and characterization of glycan structures. These tools enable researchers to map the glycome—the entire set of glycans in an organism or tissue—faster and with greater accuracy than ever before. This capability is crucial for understanding how glycans differ across tissues, individuals, or disease states, paving the way for more personalized medical treatments.

Another key technological advancement is the application of bioinformatics tools to glycomics research. The complexity of glycan structures, with their numerous branches and diverse configurations, requires sophisticated computational methods for analysis and interpretation. Advances in machine learning and artificial intelligence (AI) are enabling the development of algorithms that can predict glycan structures and their interactions with proteins and lipids. These bioinformatics tools help researchers identify glycan biomarkers for diseases, develop glycan-based therapeutics, and uncover how glycan alterations contribute to disease progression. With AI-driven analytics, scientists can sift through vast amounts of glycomic data to identify patterns and potential therapeutic targets more efficiently.

Advances in synthetic glycobiology are also transforming the field by enabling the design and production of synthetic glycans. These synthetic glycans mimic naturally occurring molecules and are used in vaccine development, drug discovery, and therapeutic research. For instance, researchers can create specific glycan structures to study how pathogens interact with human cells or to develop vaccines that elicit strong immune responses. This capability is particularly important for developing vaccines for complex viruses like influenza and coronaviruses, where glycans play a key role in immune evasion. Additionally, synthetic glycans are being used in the development of glycan-based drugs that target specific receptors on cancer cells or modulate immune responses, opening new avenues for precision medicine.

Another area of advancement is the use of advanced imaging techniques, such as cryo-electron microscopy (cryo-EM) and glycan array technology. These tools allow scientists to visualize how glycans interact with other biomolecules at the molecular level. This is crucial for understanding the role of glycans in processes like cell signaling, pathogen recognition, and immune system function. Glycan arrays, for example, enable the high-throughput screening of glycan interactions with proteins, which can reveal potential drug targets or biomarkers for diseases like cancer and neurodegenerative disorders. These imaging and screening technologies are providing deeper insights into the dynamic role of glycans in health and disease.

Why Is Glycomics Critical for Understanding Disease Mechanisms, Developing Diagnostics, and Advancing Therapeutics?

Glycomics is critical for understanding disease mechanisms, developing diagnostics, and advancing therapeutics because glycans play a fundamental role in regulating biological processes and disease progression. Glycans are involved in nearly every aspect of cellular function, from protein folding and stability to immune system activation and cell-cell communication. Alterations in glycan structures are often associated with disease states, making glycomics an invaluable tool for identifying biomarkers and understanding disease mechanisms at a molecular level.

One of the most important contributions of glycomics to medicine is its ability to uncover biomarkers for early disease detection. Changes in glycosylation—the process by which glycans attach to proteins or lipids—are frequently observed in diseases like cancer, diabetes, and infectious diseases. For example, abnormal glycan patterns are a hallmark of cancer cells, where they can promote tumor growth, metastasis, and immune evasion. By identifying these altered glycan signatures, researchers can develop more sensitive and specific diagnostic tests. Glycan-based biomarkers hold the potential to revolutionize early disease detection, allowing clinicians to diagnose conditions like cancer, liver disease, and neurodegenerative disorders at earlier stages, when treatments are more likely to be effective.

In therapeutics, glycomics is enabling the development of more targeted and effective treatments. Glycan structures can serve as drug targets, particularly in diseases where abnormal glycosylation is involved. For instance, certain cancers exhibit unique glycan patterns on their surface proteins, and glycomics research is leading to the development of therapies that specifically target these aberrant glycans. These glycan-targeting therapies offer a more precise approach to treatment, minimizing damage to healthy tissues while focusing on the diseased cells. Glycomics is also contributing to the design of glycan-based vaccines that enhance immune recognition of pathogens or cancer cells. Glycans play a crucial role in how the immune system identifies foreign invaders, and vaccines that incorporate synthetic glycans can trigger stronger and more specific immune responses.

Glycomics is also essential for the development of biologics, a growing class of therapeutics that includes monoclonal antibodies, gene therapies, and cell-based treatments. Many biologics, such as therapeutic antibodies, rely on glycosylation for their stability, efficacy, and safety. Understanding and controlling glycosylation patterns during drug manufacturing is critical for ensuring that biologics function correctly and are safe for patients. Glycomics provides the tools needed to monitor and optimize glycosylation during production, helping pharmaceutical companies develop more effective and consistent biologic therapies.

In addition to therapeutics and diagnostics, glycomics is playing a pivotal role in advancing personalized medicine. Since glycan patterns can vary between individuals based on genetic and environmental factors, understanding these variations allows for the development of personalized treatments tailored to a patient’s specific glycan profile. This is particularly important in cancer, where tumors often exhibit unique glycosylation patterns that can be targeted with personalized therapies. As the field of glycomics continues to evolve, it will play an increasingly important role in shaping the future of precision medicine, enabling more effective treatments that are customized to individual patients’ molecular profiles.

What Factors Are Driving the Growth of the Glycomics/Glycobiology Market?

Several key factors are driving the rapid growth of the glycomics/glycobiology market, including the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. First, the push toward personalized medicine is a major driver of the glycomics market. As healthcare shifts from a one-size-fits-all approach to more individualized treatments, glycomics offers the tools to identify unique glycan profiles that can be used to tailor therapies. This is particularly important in oncology, where cancer cells often exhibit specific glycan changes that can be targeted for more effective treatments. The ability to use glycan biomarkers for early disease detection and personalized treatment strategies is fueling the demand for glycomics technologies in research and clinical settings.

Second, advancements in drug development, particularly in the field of biologics and monoclonal antibodies, are contributing to the growth of the glycomics market. Many biologic drugs rely on glycosylation for their activity, stability, and safety, and controlling these glycan structures during drug production is essential for creating effective therapies. Pharmaceutical companies are increasingly investing in glycomics tools and technologies to optimize glycosylation in biologics, ensuring that these therapies meet the highest standards for efficacy and safety. This demand for precision in drug development is driving the adoption of glycomics in the pharmaceutical industry.

Third, the growing prevalence of complex diseases, such as cancer, autoimmune disorders, and neurodegenerative diseases, is increasing the need for advanced diagnostic and therapeutic solutions. Glycomics is uniquely positioned to address this need by offering insights into how changes in glycosylation contribute to disease progression. For example, glycan-based biomarkers are being developed for the early detection of cancers, while glycan-targeting therapies are being explored as novel treatments for autoimmune diseases and infectious diseases. As the global burden of these diseases continues to rise, the demand for glycomics-based solutions is expected to grow significantly.

Technological innovations in glycan analysis are also driving the expansion of the glycomics market. Advances in mass spectrometry, glycan arrays, and bioinformatics tools are enabling researchers to analyze glycans with greater speed, accuracy, and resolution. These technologies are making it easier for scientists to map the glycome, identify disease-specific glycan alterations, and develop new glycan-based therapies. The growing availability of high-throughput glycan analysis tools is accelerating research and expanding the commercial potential of glycomics in fields such as diagnostics, therapeutics, and vaccine development.

Additionally, increased funding for glycomics research and the establishment of specialized glycomics research centers are contributing to market growth. Governments, academic institutions, and private companies are investing heavily in glycomics research due to its potential to transform healthcare. Collaborative efforts between academia, industry, and healthcare providers are advancing the application of glycomics in clinical practice, further driving demand for glycomics tools and technologies.

In conclusion, the growth of the glycomics/glycobiology market is being driven by the increasing demand for personalized medicine, advancements in drug development, the growing prevalence of complex diseases, and technological innovations in glycan analysis. As glycomics continues to provide deeper insights into the role of glycans in health and disease, it will play a crucial role in shaping the future of diagnostics, therapeutics, and precision medicine across a wide range of medical and industrial applications.

Select Competitors (Total 152 Featured) -

  • Agilent Technologies, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Merck KgaA
  • New England Biolabs, Inc.
  • Prozyme, Inc.
  • Shimadzu Corporation
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Waters Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Glycomics / Glycobiology - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Interest in Glycomics for Understanding Disease Mechanisms Spurs Market Growth
    • Expansion of Glycobiology in Cancer and Immunology Research Drives Demand
    • Role of Glycomics in Developing Targeted Therapies and Personalized Medicine
    • Market Opportunities in Drug Discovery and Development Utilizing Glycomics
    • Role of Glycomics in Vaccine Development and Infectious Disease Research
    • Consumer Demand for Glycan-based Diagnostics and Biomarkers
    • Expansion of Glycomics in Neurological Research and Neurodegenerative Diseases
    • Role of Glycomics in Enhancing Stem Cell and Regenerative Medicine Research
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glycomics / Glycobiology Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glycomics / Glycobiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Enzymes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Enzymes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Discovery & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Drug Discovery & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • JAPAN
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Japan 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • CHINA
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: China 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • EUROPE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Glycomics / Glycobiology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Glycomics / Glycobiology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • FRANCE
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: France 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • GERMANY
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Germany 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Italy 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: UK 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Europe 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Glycomics / Glycobiology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Asia-Pacific 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Glycomics / Glycobiology by Product - Enzymes, Kits & Reagents and Instruments Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Product - Percentage Breakdown of Value Sales for Enzymes, Kits & Reagents and Instruments for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Glycomics / Glycobiology by Application - Drug Discovery & Development, Diagnostics and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of World 16-Year Perspective for Glycomics / Glycobiology by Application - Percentage Breakdown of Value Sales for Drug Discovery & Development, Diagnostics and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Glycomics / Glycobiology by End-Use - Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of World 16-Year Perspective for Glycomics / Glycobiology by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes, Pharma & Biotech Companies and Contract Research Organizations for the Years 2014, 2024 & 2030

IV. COMPETITION